Loncastuximab tesirine-lpyl (Zynlonta®) against CD19, approved for blood cancer in 2021, was internalized via RME and released the cytotoxic molecule SG3199 by lysosomal proteolysis and the subsequent self-motivated degradation of the linker [34]. Here, CD19 is linked to hematopoietic and lymphoid system neoplasm.